Intensity Therapeutics, Inc. · NASDAQ:INTS
Intensity Therapeutics — IPO Roadshow (November 2021)
21 slides from Intensity Therapeutics's IPO roadshow presentation, Nov 24, 2021
Slide 1: A New Weapon in the War on Cancer
October 2021 A NEW WEAPON IN THE WAR ON CANCER Directly killing tumors to activate a patient - specific immune response Treating all stages of cancer November 2021 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 260565
Slide 2: Safe Harbor and Forward-Looking Statements
2 2 SAFE HARBOR AND FORWARD - LOOKING STATEMENTS Intensity Therapeutics, Inc. (the “Company” or “we”) has filed a registration statement, including a preliminary prospectus, wit h the U.S. Securities and Exchange Commission (the “SEC”) (File No. 333 - 260565) in connection with the offering to which
Slide 3: Offering Summary
Issuer Intensity Therapeutics Symbol INTS Intended Listing Exchange NASDAQ Capital Market Offering Size $17.25 Million (includes 15% overallotment) Securities Offered 1.5 million shares of Common Stock (does not include 15% overallotment) Price Range $9 – $11 Expected Use of Proceeds • Phase 3 sarco
Slide 4: Management Team: Extensive Oncology and Drug Development Experience
4 MANAGEMENT TEAM: EXTENSIVE ONCOLOGY AND DRUG DEVELOPMENT EXPERIENCE Lewis H. Bender , MIT ChE, MS, MA, MBA • CEO, CTO, VP, BD & Manufacturing: Emisphere • CEO: Genomic testing, Interleukin Genetics • Roche, Manufacturing • Drug delivery expertise Preclinical • through Phase 3 • Public biotech comp
Slide 5: Investment Highlights
5 INVESTMENT HIGHLIGHTS Localized Cancer Kill Leading to Immune Activation and Extended Survival • Novel drug product candidates containing amphiphilic molecules • Favorable safety with efficacy; 115 patients treated through September 30, 2021 • No maximum tolerated dose; adverse events are mostly l
Slide 6: Multiple Late Stage Pipeline Programs
6 PRECLINICAL PHASE 1 PHASE 2 PHASE 3 INT230 - 6 Colorectal, Bile Duct, Pancreatic Squamous cell cancers Sarcoma, Breast, Hepatic Cancers Combo with + BMS’ Yervoy® Combo with Merck’s Keytruda® (non - immunogenic “cold tumors”) Randomized Controlled INT230 - 6 TNBC* (Neoadjuvant) MULTIPLE LATE STAGE
Slide 7: Our Delivery Technology Is Based on a Proven Science
7 OUR DELIVERY TECHNOLOGY IS BASED ON A PROVEN SCIENCE AMPHIPHILIC MOLECULES ARE SOLUBLE IN FAT AND WATER SIMULTANEOUSLY Technology First Developed for Oral Semaglutide Tablets (Rybelsus) Intensity’s ISSUED patents claim use with therapeutic agents for intratumoral delivery Intensity has patent prot
Slide 8: DfuseRx Proprietary Drug Discovery Platform
8 DFUSERX SM PROPRIETARY DRUG DISCOVERY PLATFORM PRODUCT CANDIDATE: INT230 - 6 – CONTAINS PROVEN ANTI - CANCER AGENTS INT230 - 6: designed for intratumoral (IT) use; scaled - up, stable, reproducible INT230 - 6 vials contains the amphiphilic agent (SHAO) with 2 potent cytotoxic drugs Amphiphilic Mol
Slide 9: A Unique, Anti-Cancer Therapy
9 INT230 - 6: A UNIQUE, ANTI - CANCER THERAPY 100% WATER SOLUTION THAT DISPERSES, DIFFUSES AND IS HIGHLY RETAINED IN TUMORS – DOES NOT HARM HEALTHY TISSUE *Tumors contain high percentages of fat and are under high pressure CYTOTOXICS DRUG + dye in water Little to no drug dispersion in all tumors tes
Slide 10: Clinical Studies as of September 30, 2021
10 CLINICAL STUDIES AS OF SEPTEMBER 30, 2021 RESULTS AS OF 9/30/2021 • METASTATIC REFRACTORY CANCERS: 95 PATIENTS TREATED • EARLY - STAGE BREAST CANCER: 20 PATIENTS TREATED Attacking the Tumors – Sparing the Patient
Slide 11: Causes Tumors to Become Highly Necrotic
11 INT230 - 6 CAUSES TUMORS TO BECOME HIGHLY NECROTIC A CASE FROM OUR METASTIC STUDY PATIENT: Multiple surgeries, radiation, chemotherapy • (Jan ’18), Two 10 cm 3 deep nodules appear in upper arm • MD’s Recommendation: Total arm and shoulder amputation Subject received 4 doses of INT230 - 6 equal to
Slide 12: INVINCIBLE Study: Necrosis Achieved in Early Invasive Breast Cancer
12 PHASE 2 INVINCIBLE STUDY: NECROSIS ACHIEVED IN PROLIFERATING EARLY, INVASIVE BREAST CANCER (WHOLE TUMOR RESECTIONS) DOSE DEPENDENT DIFFUSION AND HIGH PERCENTAGE OF TUMOR KILLING OBSERVED Patient #14: 3.9 cm invasive ductal cancer: Grade 3 (high grade): ER+PR+Her2+ 2 injections Final Pathology (si
Slide 13: Immune Activation Observed in Multiple Cancer Types
13 IMMUNE ACTIVATION OBSERVED IN MULTIPLE CANCER TYPES AT 28 DAYS MODIFICATION OF THE TUMOR MICROENVIRONMENT OBSERVED Biopsies taken on day 0 and 28 INT230 - 6 dosed twice: Day 0 and Day 14 • Blue color indicates live cancer, DAPI; Green & yellow indicates immune cells Multiplex IHC shows: • Decreas
Slide 14: Potential Treatment of Advanced Sarcoma
14 POTENTIAL TREATMENT OF ADVANCED SARCOMA HIGH UNMET MEDICAL NEED – SIGNIFICANT MARKET POTENTIAL 19 metastatic sarcoma subjects treated as of July 31, 2021 • Sarcomas are cancers of soft tissues such as fat, muscle, nerves, (STS) and bone (osteosarcoma) • 12,000 are diagnosed per year in the U.S •
Slide 15: Extends Survival Compared to Historical Phase 1/2 Results in aSTS
15 INT230 - 6 EXTENDS SURVIVAL COMPARED TO HISTORICAL PHASE 1/2 RESULTS IN ADVANCED SOFT TISSUE SARCOMAS (aSTS) 0% 20% 40% 60% 80% 100% 0 100 200 300 400 Survival Probability Survival Days All, n=19 All dosed >40% TTB, n=15 Mono dosed >40% TTB, n=7 INT230-6+Checkpoint Inhibitor dosed >40% TTB, n=8 K
Slide 16: Phase 3 Trial Design in Soft Tissue Sarcoma
16 PHASE 3 TRIAL DESIGN FOR INT230 - 6 IN SOFT TISSUE SARCOMA (STS) EXPECTED TO OFFER SURVIVAL IMPROVEMENT VS CURRENT 2 ND AND 3 RD LINE SOC Median OS Curve for STS standard of care drugs and projected INT230 - 6 in Phase 3 • Intent to treat (ITT) population: all STS • Size: N=331 • Enrollment: 2:1
Slide 17: Platform Validated by World Leading Partnerships
17 PLATFORM VALIDATED BY WORLD LEADING PARTNERSHIPS RESEARCH CLINICAL TRIAL SITES
Slide 18: Multiple Upcoming Milestones 2021 to 2023
18 MULTIPLE UPCOMING MILESTONES 2021 to 2023 MILESTONES TIMING Society for Immunotherapy of Cancer (SITC) 2021: Report safety and efficacy data of monotherapy and I/O combinations Q4 2021 Connective Tissue Oncology Society (CTOS 2021): Oral podium presentation of INT230 - 6 in S arcoma Q4 2021 Repor
Slide 19: Capitalization Table Pre and Post IPO
19 CAPITALIZATION TABLE PRE AND POST IPO Security Type Pre - IPO # of Shares Post IPO 1 Common – Lewis H. Bender (Founder) 4,000,000 4,000,000 Common – Prior holder 2,820,211 2,820,211 Subtotal of Common Shares Prior holders 6,820,211 6,820,211 New Share holders - 1,500,000 Subtotal of Common Shares
Slide 20: INTS Investment Summary
20 INTS INVESTMENT SUMMARY Novel Technology to Kill Cancer and Activate the Immune System; Extended Patient Survival Favorable safety; 115 patients treated as of September 30, 2021 On - going Phase 2 Studies; Phase 3 Registration Study Designed in Sarcomas with FDA Alignment FDA Fast Track designati
Slide 21: Intensity Therapeutics: A New Weapon to Treat Cancer
21 INTENSITY THERAPEUTICS A NEW WEAPON TO TREAT CANCER Contact Investor Relations Contact: Rx Communications Group Michael Miller (917) - 633 - 6086 mmiller@rxir.com Thank you!
Intensity Therapeutics — IPO Roadshow (November 2021) on 6ix